Open Pharma position statement on open access

Chris Winchester
CEO, Oxford PharmaGenesis
MedComms Networking Brunch, 21 October 2019
Chris Winchester is an Employee and Director of Oxford PharmaGenesis Ltd, a Director and Shareholder of Oxford PharmaGenesis Holdings Limited and a Director of Oxford Health Policy Forum CIC.
Why do we need research transparency?

Approximately **59%** of the public trust research by university scientists ‘**completely’** or ‘**a great deal’** …

… this falls to just **32%** of the public who report the same trust in research by the pharmaceutical industry

Pharmaceutical companies now disclose the results of nearly all their clinical trials.
Why might the public report less trust in pharma?

“...A paywall may restrict the number of readers, and this might NOT help the reputation of the pharmaceutical industry (the mindset of it being a bit secretive).”

*Alan Thomas, Ataxia & Me*
Some publishers prevent companies from publishing unrestricted open access

- In a study of 35 medical journals with a high impact factor, 21 (60%) offered an immediate open access option with a Creative Commons licence
- Of these 21 journals:
  - CC BY was offered by 100% (21/21)
  - CC BY-NC was offered by 19% (4/21)
  - CC BY-NC-ND was offered by 86% (18/21)
- Only one of these 21 journals potentially offered immediate open access under a CC BY licence to authors irrespective of their funding source

Journals only offering CC BY open access for research funded by specific non-commercial organizations

Journals offering CC BY open access to organizations that require it

BY, Attribution; CC, Creative Commons; NC, Non-Commercial; ND, No Derivatives

Ellison T, Koder T, Schmidt L, Williams A, Winchester C. Open access policies of leading medical journals: a cross-sectional study. 

BMJ Open 2019;9:e028655
Our purpose

Open Pharma aims to connect pharma with innovations in publishing to achieve a …

- **transparent** publishing process …

- with **accessible** outputs …

- that are available **quickly** …

- using an **efficient, sustainable** process
Our workstreams

Open access
- Increased readership of research
- Increased transparency

Preprints and post-publication peer review
- Faster dissemination of results
- Faster citation and use of results

ORCID, CRedit and Convey
- Increased transparency, reduced administrative burden
- More accountability

Layered publication platforms
- Complete information available from a single point
- Targeted content for each user group
The launch of the Open Pharma position statement on open access
The launch of the Open Pharma position statement on open access

Open access ensures that the highest quality peer-reviewed evidence is available to anyone who needs it, anywhere in the world.

- Advance medical science
- Improve patient care
- Increase transparency
- Globalize communication
- Accelerate dissemination
- Increase dissemination
- Globalize communication
Our objectives

Our immediate priority

Secure authors publishing company-funded research the same right to publish open access as authors publishing research funded by other sources

All research to be made free to read from the date of publication

Any variant of Creative Commons or equivalent licence

BY, Attribution; CC, Creative Commons
### Our objectives

<table>
<thead>
<tr>
<th>Our immediate priority</th>
<th>Our long-term goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secure authors publishing company-funded research the <strong>same right to publish open</strong></td>
<td>Secure authors publishing company-funded research the <strong>same terms</strong> as authors....</td>
</tr>
<tr>
<td><strong>access</strong> as authors publishing research funded by other sources</td>
<td>publishing research funded by other sources</td>
</tr>
<tr>
<td>All research to be made <strong>free to read from the date of publication</strong></td>
<td>Free to read – <strong>and reuse</strong> – from the date of publication</td>
</tr>
<tr>
<td>Any variant of Creative Commons or equivalent licence</td>
<td>Sustainable use of <strong>CC BY</strong></td>
</tr>
</tbody>
</table>

**CC BY**, Attribution; CC, Creative Commons
We thank all supporters and followers of Open Pharma for their valuable input.

Contributors

Catherine Skobe
Senior Director, Publications Innovative Solutions Lead, Pfizer

Chris Rains
Head of GMA Medical Functions, Takeda

Chris Winchester
CEO, Oxford PharmaGenesis

Julie Newman
Associate Director, HIV, Gilead

Lise Baltzer
Director of Global Publications, Novo Nordisk

Sarah Sabir
Medical Writer, Oxford PharmaGenesis

Valerie Philippon
Head, Global Publications, Takeda
Endorsed by academics, publishers, biopharmaceutical companies and patients

Individuals

Alan Thomas, Ataxia & Me
Gavin Giovannoni, Barts and the London School of Medicine and Dentistry
Martin Delahunty, Inspiring STEM
Robert Sim, Department of Respiratory Science, Leicester University
Pali Hungin, Newcastle University
Kajsa Wilhelmsson, Oxford Health System Reform Group
Elizabeth Kinder, patient advocate
Richard Stephens, patient advocate
Angela Sykes, Pfizer
Courtney Leo, Pfizer
J. R. Meloro, Pfizer
Ellie Challis, PTEN UK & Ireland
Dermot Ryan, Respiratory Effectiveness Group

Victoria Woods, Quality Improvement Lead – Patient and Public Engagement, Thames Valley Cancer Alliance at NHS England
Zbys Fedorowicz, The Care Combine and North West Anglia, NHS Foundation Trust
Stuart Taylor, The Royal Society
Erik Michels, UCB Pharma
Meredith Hays, Department of Medicine, Uniformed Services University
Stephen Bradley, University of Leeds
Chas Bountra, Professor of Translational Medicine, Nuffield Department of Clinical Medicine, University of Oxford
Edith Sim, Professor Emeritus, Department of Pharmacology, University of Oxford
Stevan Harnad, University of Southampton
Alvaro Diaz, Departamento de Biociencias, Universidad de la República de Uruguay

Correct as of 21 October 2019
Endorsed by academics, publishers, biopharmaceutical companies and patients

Organizations

Ataxia & Me
Cambridge Rare Disease Network
Galapagos NV
Kidney Research UK
Observational and Pragmatic Research Institute Pte
Oxford Health Policy Forum
Oxford PharmaGenesis
SUDEP Action
ThinkSCIENCE, Inc.

Publishers

F1000 Research Ltd
Wiley

Correct as of 21 October 2019
I recently met a physician from Southern Africa engaged in perinatal HIV prevention, whose primary access to information was abstracts posted on the Internet. Based on a single abstract, they had altered their perinatal HIV prevention programme from an effective therapy to one with lesser efficacy.

Had they read the full-text article they would have undoubtedly realized that the study results were based on short-term follow-up, a small pivotal group [and] incomplete data, and [were] unlikely to be applicable to their country’s situation. Their decision to alter treatment based solely on the abstract’s conclusions may have resulted in increased perinatal HIV transmission.

Professor Arthur Ammann
Co-founder of Global Strategies for HIV Prevention

HIV, human immunodeficiency virus
Open Pharma needs you!

Do you agree with our position statement on open access?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit the Open Pharma site, review the statement and endorse it</td>
<td>Tell us why</td>
</tr>
<tr>
<td>Encourage others to do the same, within your organization and on social media</td>
<td></td>
</tr>
</tbody>
</table>

Help us to share the news!

Sign our position statement today!

Get involved with the conversation

@_OpenPharma
#openpharma #OAWeek #openaccess #openforall

https://openpharma.blog/